In Silico Study Synthesis and Biological Evaluation of Some Benzopyran Benzotriazole Hybrids

Abstract

The study conducted an in-silico docking investigation on 60 benzopyran-3-carbonyl derivatives, focusing on antihyperlipidemic, long fatty acid chain enoyl-ACP reductase, and -amylase activities. Significant docking scores indicated the efficacy of compounds D10, D12, E14, F6, F7, and F13, with 3,4-diaminobenzoic acid as the starting material. Combining 1H-benzotriazole-5-carboxylic acid with 5-chloro-2-hydroxybenzaldehyde, 2,2-dimethyl-1,3-dioxane-4,6-dione, and 1-(6-chloro-2-oxo-3,4-dihydro-2H-1-benzopyran-3-carbonyl) produces various chemicals, identified using various spectroscopic methods. The intermediates were transformed into benzopyran derivatives, with good yield and purity. FTIR tests showed peaks around 1400-1790 cm-1 C=O stretch. Fenofibrate showed the greatest triglyceride and VLDL level reduction. Benzopyran-3-carbonyl derivatives reduced triglyceride and VLDL levels. The study found that 200 mg/kg of benzopyran-3-carbonyl derivatives significantly increased blood HDL levels in diabetic rats, while also inhibiting and#945;-amylase activity. These derivatives showed appreciable inhibitory effects compared to acarbose. The use of these derivatives was applied to all animals, preventing severe insulin shortage and increasing fasting blood glucose levels. Animal tests show moderate to poor antihyperglycemic action, except for benzopyran-3-carbonyl derivatives, which significantly lower blood glucose AUC. No statistically significant differences were found in MICs for M. tuberculosis or M. avium strains, with fluorometric MABA MICs corresponding to visual MABA MICs. In vitro studies on L-6 cell lines showed that benzopyran-3-carbonyl derivatives improved glucose absorption by 27.55 to 32.64%. Compared to metformin and insulin, these drugs increased glucose absorption by 141.65 to 153.82% and 73.00 to 84.55%, respectively. However, no synergistic effect was found.